Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Jun 20, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1 invites investors and the general public to...
-
Jun 12, 2018-- Novel discovery improves the immunological activity of certain cancer fighting antibodies
A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting...
-
Jun 6, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Jennifer Buell, Ph.D.,...
-
Jun 4, 2018- AGEN1884 and AGEN2034 produce clinical benefit2 in 31% and 42% of patients respectively
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, today presented updated clinical data on its...
-
May 17, 2018- AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced that data on its proprietary...
-
May 7, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Garo Armen, Ph.D.,...
-
May 7, 2018Agenus to host conference call and webcast today at 11am ET
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported...
-
May 3, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will release its first quarter 2018 financial...
-
May 1, 2018
AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today...
-
Apr 11, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that three abstracts were accepted for presentation at...
